MRTX — Mirati Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $4.12bn
- $3.15bn
- $12.44m
Annual income statement for Mirati Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.9 | 3.33 | 13.4 | 72.1 | 12.4 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 11.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 116 | 225 | 383 | 645 | 772 |
| Operating Profit | -103 | -222 | -369 | -573 | -760 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -98.4 | -213 | -358 | -578 | -740 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -98.4 | -213 | -358 | -582 | -741 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -98.4 | -213 | -358 | -582 | -741 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -98.4 | -213 | -358 | -582 | -741 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.19 | -5.69 | -7.96 | -11.2 | -13.2 |